269 related articles for article (PubMed ID: 19465145)
21. Social acceptability of methylphenidate and behavior modification for treating attention deficit hyperactivity disorder.
Liu C; Robin AL; Brenner S; Eastman J
Pediatrics; 1991 Sep; 88(3):560-5. PubMed ID: 1881737
[TBL] [Abstract][Full Text] [Related]
22. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD.
Flapper BC; Schoemaker MM
Dev Med Child Neurol; 2008 Apr; 50(4):294-9. PubMed ID: 18352997
[TBL] [Abstract][Full Text] [Related]
23. Investigation of genotoxic effect of ultrasound in cases receiving therapeutic ultrasound by using micronucleus method.
Sahin O; Dönmez-Altuntaş H; Hizmetli S; Hamurcu Z; Imamoğlu N
Ultrasound Med Biol; 2004 Apr; 30(4):545-8. PubMed ID: 15121257
[TBL] [Abstract][Full Text] [Related]
24. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
[TBL] [Abstract][Full Text] [Related]
25. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
Brams M; Mao AR; Doyle RL
Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
[TBL] [Abstract][Full Text] [Related]
26. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD.
Witt KL; Shelby MD; Itchon-Ramos N; Faircloth M; Kissling GE; Chrisman AK; Ravi H; Murli H; Mattison DR; Kollins SH
J Am Acad Child Adolesc Psychiatry; 2008 Dec; 47(12):1375-83. PubMed ID: 18978633
[TBL] [Abstract][Full Text] [Related]
27. Methylphenidate and chromosome damage.
Jacobson-Kram D; Mattison D; Shelby M; Slikker W; Tice R; Witt K
Cancer Lett; 2008 Feb; 260(1-2):216-8. PubMed ID: 18055105
[No Abstract] [Full Text] [Related]
28. Empirical, ethical, and political perspectives on the use of methylphenidate.
McCubbin M; Cohen D
Ethical Hum Sci Serv; 1999; 1(1):81-101. PubMed ID: 15278982
[TBL] [Abstract][Full Text] [Related]
29. Dissociation in response to methylphenidate on response variability in a group of medication naïve children with ADHD.
Johnson KA; Barry E; Bellgrove MA; Cox M; Kelly SP; Dáibhis A; Daly M; Keavey M; Watchorn A; Fitzgerald M; McNicholas F; Kirley A; Robertson IH; Gill M
Neuropsychologia; 2008 Apr; 46(5):1532-41. PubMed ID: 18289615
[TBL] [Abstract][Full Text] [Related]
30. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.
Kim Y; Shin MS; Kim JW; Yoo HJ; Cho SC; Kim BN
Hum Psychopharmacol; 2009 Mar; 24(2):95-102. PubMed ID: 19226534
[TBL] [Abstract][Full Text] [Related]
31. Effects of application to two different skin sites on the pharmacokinetics of transdermal methylphenidate in pediatric patients with attention-deficit/hyperactivity disorder.
González MA; Campbell D; Rubin J
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):227-32. PubMed ID: 19519257
[TBL] [Abstract][Full Text] [Related]
32. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH).
Hagmar L; Bonassi S; Strömberg U; Brøgger A; Knudsen LE; Norppa H; Reuterwall C
Cancer Res; 1998 Sep; 58(18):4117-21. PubMed ID: 9751622
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
[TBL] [Abstract][Full Text] [Related]
34. DNA damage in rats after treatment with methylphenidate.
Andreazza AC; Frey BN; Valvassori SS; Zanotto C; Gomes KM; Comim CM; Cassini C; Stertz L; Ribeiro LC; Quevedo J; Kapczinski F; Berk M; Gonçalves CA
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1282-8. PubMed ID: 17614179
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, dose-range, and mutagenicity studies of methylphenidate hydrochloride in B6C3F1 mice.
Manjanatha MG; Shelton SD; Dobrovolsky VN; Shaddock JG; McGarrity LG; Doerge DR; Twaddle NW; Lin CJ; Chen JJ; Mattison DR; Morris SM
Environ Mol Mutagen; 2008 Oct; 49(8):585-93. PubMed ID: 18618596
[TBL] [Abstract][Full Text] [Related]
36. Sequential evaluation of behavioral treatments and methylphenidate dosage for children with attention deficit hyperactivity disorder.
Gulley V; Northup J; Hupp S; Spera S; LeVelle J; Ridgway A
J Appl Behav Anal; 2003; 36(3):375-8. PubMed ID: 14596580
[TBL] [Abstract][Full Text] [Related]
37. Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder.
Cheon KA; Jun JY; Cho DY
Int Clin Psychopharmacol; 2008 Sep; 23(5):291-8. PubMed ID: 18703939
[TBL] [Abstract][Full Text] [Related]
38. [Neuropsychological assessment of the effectiveness of OROS-methylphenidate in attention deficit hyperactivity disorder].
Rubio-Morell B; Martín-González R; Herreros-Rodríguez O; González-Pérez P; Hernández-Exposito S; Quintero-Fuentes I; Gracia-Marco R
Rev Neurol; 2008 May 16-31; 46(10):602-8. PubMed ID: 18465700
[TBL] [Abstract][Full Text] [Related]
39. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
40. Characterization of anxiety-related responses in male rats following prolonged exposure to therapeutic doses of oral methylphenidate.
Britton GB; Bethancourt JA
Pharmacol Biochem Behav; 2009 Oct; 93(4):451-9. PubMed ID: 19540871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
